Side effects of therapy for chronic hepatitis C

Gastroenterology

Volumn 124, Issue 6, 2003, Pages 1711-1719

  Russo, Mark W ^a   Fried, Michael W ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYCLOOXYGENASE 2 INHIBITOR; ERYTHROPOIETIN; FLUVOXAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBUPROFEN; NEFAZODONE; PARACETAMOL; PAROXETINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; VIRUS RNA;

ADDISON DISEASE; ALOPECIA; AMNESIA; ANEMIA; ANOREXIA; ARTHRALGIA; BRONCHIOLITIS; CELIAC DISEASE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DERMATITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEARING LOSS; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFLAMMATION; INJECTION SITE; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL LUNG DISEASE; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; META ANALYSIS; MOTOR NEUROPATHY; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PATIENT COMPLIANCE; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RETINA HEMORRHAGE; REVIEW; RIGOR; SARCOIDOSIS; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; SKIN MANIFESTATION; SUICIDAL BEHAVIOR; THROMBOCYTOPENIA; TINNITUS; WEIGHT REDUCTION;

EID: 0037517079     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00394-9     Document Type: Review

References (63)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, et al. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
3. Fried MW. Side effects of therapy for hepatitis C and their management. Hepatology 2002;36:S237-S244.
4. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002;123:2082-2099.
5. Ferenci P, Shiffman ML, Fried MW, Sulkowski MS, Haeussinger D, Zarski J-P, Goncales FL, et al. Early prediction of response to 40KDA peginterferon alfa-2a (PEGASYS) plus ribavirin in patients with chronic hepatitis C. Hepatology 2001;34:351A
6. Hadziyannis SJ. Hepatology 2002.
7. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, Gangl A, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002;123:141-151.
8. Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001;34:911-916.
9. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004.
10. Dieterich DT, Pockros P, Schiff ER, et al. Interim results of a randomized, double-blind placebo-controlled study demonstrates that epoietin-alfa (PROCRIT) allows maintenance of ribavirin dosing (abstr). Hepatology 2002;493.
11. Devine EB, Kowdley KV, Veenstra DL, Sullivan SD. Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications. Value Health 2001;4:376-384.
12. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, Park Y, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-1279.
13. Higashi Y, Sakai K, Tada S, Miyase S, Nakamura T, Kamio T, Haraguchi O. Case report: agranulocytosis induced by interferon-alpha therapy for chronic hepatitis C. J Gastroenterol Hepatol 1996;11:1012-1015.
14. Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, Kania RJ, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995;42:907-912.
15. Fukuda A, Kobayashi H, Teramura K, Yoshimoto S, Ohsawa N. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines Cell Mol Ther 2000;6:149-154.
16. Carreno V, Martin J, Pardo M, Brotons A, Anchia P, Navas S, Fernandez M, et al. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C. Cytokine 2000;12:165-170.
17. Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. J Hepatol 1998;28:382-389.
18. Hoofnagle J. Thrombocytopenia during interferon alpha therapy (abstr). JAMA 1991;266:849.
19. Shrestha R, McKinley C, Bilir BM, Everson GT. Possible idiopathic thrombocytopenic purpura associated with natural alpha interferon therapy for chronic hepatitis C infection. Am J Gastroenterol 1995;90:1146-1147.
20. Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002;97:2040-2045.
21. Peck-Radosavljevic M, Wichlas M, Pidlich J, Sims P, Meng G, Zacherl J, Garg S, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998;28:1424-1429.
22. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000;157:867-876.
23. Zdilar D, Franco-Bronson K, Buchier N, Locala JA, Younossi ZM-Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-1211.
24. Nguyen HA, Miller AI, Dieperink E, Willenbring ML, Tetrick LL, Durfee JM, Ewing SL, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002;97:1813-1820.
25. Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000;18:107-116.
26. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22:86-90.
27. Farkkila M, livanainen M, Harkonen M, Laakso J, Mattson K, Niiranen A, Larsen TA, et al. Effect of interferon-gamma on biogenic amine metabolism, electroencephalographic recordings, and transient potentials. Clin Neuropharmacol 1988;11:63-67.
28. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, Almerighi C, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001;105:45-55.
29. Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, Bauer J, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 2000;152:383-389.
30. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37:443-451.
31. Kraus MR, Schafer A, Csef H, Faller H, Mork H, Scheurlen M. Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci 2001;46:2060-2065.
32. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-1099.
33. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7:942-947.
34. Epstein SA. Psychotropic medications in gastrointestinal and hepatic disease. Adv Psychosom Med 1994;21:49-60.
35. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999;57:507-533.
36. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-243.
37. Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: A prospective controlled study. Clin Endocrinol (Oxf) 1999;50:503-509.
38. Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo C, Sorvillo F, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001;86:1925-1929.
39. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, Garcia-Monzon C, Arranz A, Borque MJ, Moreno-Otero R. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996;44:635-642.
40. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994;89:399-403.
41. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997;26:206-210.
42. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, Regnier D, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993;18:253-257.
43. Matsuda J, Saitoh N, Gotoh M, Gohchi K, Tsukamoto M, Syoji S, Miyake K, et al. High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol 1995;90:1138-1141.
44. Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H, von zur Muhlen A, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48:378-383.
45. Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, de Lalla F. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000;23:1177-1181.
46. Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, de Lalla F. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998;28:514-517.
47. Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002;97:2432-2440.
48. Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 1994;106:612-613.
49. Perez-Alvarez R, Perez-Lopez R, Lombrana JL, Rodriguez M, Rodrigo L. Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine. J Viral Hepat 2002;9:75-79.
50. Hoffmann RM, Jung MC, Motz R, Gossl C, Emslander HP, Zachoval R, Pape GR. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol 1998;28:1058-1063.
51. Rothfuss KS, Bode JC. Interstitial pneumonitis during combination therapy with interferon-alpha and ribavirin in a patient with chronic Hepatitis C. Z Gastroenterol 2002;40:807-810.
52. Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. Am J Med Sci 2001;322:233-235.
53. Olivieri I, Palazzi C, Padula A. Hepatitis C virus and arthritis. Rheum Dis Clin North Am 2003;29:111-122.
54. Cacoub P, Costedoat-Chalumeau N, Lidove O, Alric L. Cryoglobulinemia vasculitis. Curr Opin Rheumatol 2002;14:29-35.
55. Paoletti V, Donnarumma L, De Matteis A, Mammarella A, Labbadia G, Musca A, Francia A. Peripheral neuropathy without cryoglobulinemia in patients with hepatitis C virus infection. Panminerva Med 2000;42:175-178.
56. Khella SL, Frost S, Hermann GA, Leventhal L, Whyatt S, Sajid MA, Scherer SS. Hepatitis C infection, cryoglobulinemia, and vasculitic neuropathy. Treatment with interferon alfa: case report and literature review. Neurology 1995;45:407-411.
57. Tembl JI, Ferrer JM, Sevilla MT, Lago A, Mayordomo F, Vilchez JJ. Neurologic complications associated with hepatitis C virus infection. Neurology 1999;53:861-864.
58. Ogundipe O, Smith M. Bell's palsy during interferon therapy for chronic hepatitis C infection in patients with haemorrhagic disorders. Haemophilia 2000;6:110-112.
59. Irioka T, Yamada M, Yamawaki M, Saito Y, Mizusawa H, Miura H. Acute autonomic and sensory neuropathy after interferon alpha-2b therapy for chronic hepatitis C. J Neurol Neurosurg Psychiatry 2001;70:408-410.
60. Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 2002;25:909-913.
61. Hayasaka S, Fujii M, Yamamoto Y, Noda S, Kurome H, Sasaki M. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 1995;79:150-152.
62. Jain K, Lam WC, Waheeb S, Thai Q, Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001;85:1171-1173.
63. Kawano T, Shigehira M, Uto H, Nakama T, Kato J, Hayashi K, Maruyama T, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996;91:309-313.